Английская Википедия:CYP2D6

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Use dmy dates Шаблон:Cs1 config Шаблон:Infobox gene Cytochrome P450 2D6 (CYP2D6) is an enzyme that in humans is encoded by the CYP2D6 gene. CYP2D6 is primarily expressed in the liver. It is also highly expressed in areas of the central nervous system, including the substantia nigra.

CYP2D6, a member of the cytochrome P450 mixed-function oxidase system, is one of the most important enzymes involved in the metabolism of xenobiotics in the body. In particular, CYP2D6 is responsible for the metabolism and elimination of approximately 25% of clinically used drugs, via the addition or removal of certain functional groups – specifically, hydroxylation, demethylation, and dealkylation.[1] CYP2D6 also activates some prodrugs. This enzyme also metabolizes several endogenous substances, such as hydroxytryptamines, neurosteroids, and both m-tyramine and p-tyramine which CYP2D6 metabolizes into dopamine in the brain and liver.[1][2]

Considerable variation exists in the efficiency and amount of CYP2D6 enzyme produced between individuals. Hence, for drugs that are metabolized by CYP2D6 (that is, are CYP2D6 substrates), certain individuals will eliminate these drugs quickly (ultrarapid metabolizers) while others slowly (poor metabolizers). If a drug is metabolized too quickly, it may decrease the drug's efficacy while if the drug is metabolized too slowly, toxicity may result.[3] So, the dose of the drug may have to be adjusted to take into account of the speed at which it is metabolized by CYP2D6.[4] Individuals who have ultrarapid polymorphism, however, may metabolize prodrugs, such as codeine or tramadol, to potentially fatal levels either through breast milk[5][6][7] such as treating post-cesarian section pain. These drugs may also cause serious toxicity in ultrarapid metabolizer patients when used to treat other post-operative pain, such as after tonsillectomy.[8][9][10] Other drugs may function as inhibitors of CYP2D6 activity or inducers of CYP2D6 enzyme expression that will lead to decreased or increased CYP2D6 activity respectively. If such a drug is taken at the same time as a second drug that is a CYP2D6 substrate, the first drug may affect the elimination rate of the second through what is known as a drug-drug interaction.[3]

Gene

The gene is located on chromosome 22q13.1. near two cytochrome P450 pseudogenes (CYP2D7P and CYP2D8P).[11] Among them, CYP2D7P originated from CYP2D6 in a stem lineage of great apes and humans,[12] the CYP2D8P originated from CYP2D6 in a stem lineage of Catarrhine and New World monkeys' stem lineage.[13] Alternatively spliced transcript variants encoding different isoforms have been found for this gene.[14]

Genotype/phenotype variability

CYP2D6 shows the largest phenotypical variability among the CYPs, largely due to genetic polymorphism. The genotype accounts for normal, reduced, and non-existent CYP2D6 function in subjects. Pharmacogenomic tests are now available to identify patients with variations in the CYP2D6 allele and have been shown to have widespread use in clinical practice.[15] The CYP2D6 function in any particular subject may be described as one of the following:[16]

  • poor metabolizer – little or no CYP2D6 function
  • intermediate metabolizers – metabolize drugs at a rate somewhere between the poor and extensive metabolizers
  • extensive metabolizer – normal CYP2D6 function
  • ultrarapid metabolizer – multiple copies of the CYP2D6 gene are expressed, so greater-than-normal CYP2D6 function occurs

A patient's CYP2D6 phenotype is often clinically determined via the administration of debrisoquine (a selective CYP2D6 substrate) and subsequent plasma concentration assay of the debrisoquine metabolite (4-hydroxydebrisoquine).[17]

The type of CYP2D6 function of an individual may influence the person's response to different doses of drugs that CYP2D6 metabolizes. The nature of the effect on the drug response depends not only on the type of CYP2D6 function, but also on the extent to which processing of the drug by CYP2D6 results in a chemical that has an effect that is similar, stronger, or weaker than the original drug, or no effect at all. For example, if CYP2D6 converts a drug that has a strong effect into a substance that has a weaker effect, then poor metabolizers (weak CYP2D6 function) will have an exaggerated response to the drug and stronger side-effects; conversely, if CYP2D6 converts a different drug into a substance that has a greater effect than its parent chemical, then ultrarapid metabolizers (strong CYP2D6 function) will have an exaggerated response to the drug and stronger side-effects.[18] Information about how human genetic variation of CYP2D6 affects response to medications can be found in databases such PharmGKB,[19] Clinical Pharmacogenetics Implementation Consortium (CPIC).[20]

Genetic basis of variability

The genetic basis for CYP2D6-mediated metabolic variability is the CYP2D6 allele, located on chromosome 22. Subjects possessing certain allelic variants will show normal, decreased, or no CYP2D6 function, depending on the allele. Pharmacogenomic tests are now available to identify patients with variations in the CYP2D6 allele and have been shown to have widespread use in clinical practice.[15] The current known alleles of CYP2D6 and their clinical function can be found in databases such as PharmVar.[21]

CYP2D6 enzyme activity for selected alleles[22][21]
Allele CYP2D6 activity
CYP2D6*1 normal
CYP2D6*2 normal
CYP2D6*3 none
CYP2D6*4 none
CYP2D6*5 none
CYP2D6*6 none
CYP2D6*7 none
CYP2D6*8 none
CYP2D6*9 decreased
CYP2D6*10 decreased
CYP2D6*11 none
CYP2D6*12 none
CYP2D6*13 none
CYP2D6*14 none
CYP2D6*15 none
CYP2D6*17 decreased
CYP2D6*19 none
CYP2D6*20 none
CYP2D6*21 none
CYP2D6*29 decreased
CYP2D6*31 none
CYP2D6*38 none
CYP2D6*40 none
CYP2D6*41 decreased
CYP2D6*42 none
CYP2D6*44 none
CYP2D6*47 none
CYP2D6*50 decreased
CYP2D6*51 none
CYP2D6*68 none
CYP2D6*92 none
CYP2D6*100 none
CYP2D6*101 none
CYP2D6 duplication increased

Ethnic factors in variability

Ethnicity is a factor in the occurrence of CYP2D6 variability. The reduction of the liver cytochrome CYP2D6 enzyme occurs approximately in 7–10% in white populations, and is lower in most other ethnic groups such as Asians and African-Americans at 2% each. A complete lack of CYP2D6 enzyme activity, wherein the individual has two copies of the polymorphisms that result in no CYP2D6 activity at all, is said to be about 1-2% of the population.[23] The occurrence of CYP2D6 ultrarapid metabolizers appears to be greater among Middle Eastern and North African populations.[24][25]

Caucasians with European descent predominantly (around 71%) have the functional group of CYP2D6 alleles, producing extensive metabolism, while functional alleles represent only around 50% of the allele frequency in populations of Asian descent.[26]

This variability is accounted for by the differences in the prevalence of various CYP2D6 alleles among the populations–approximately 10% of whites are intermediate metabolizers, due to decreased CYP2D6 function, because they appear to have the one (heterozygous) non-functional CYP2D6*4 allele,[22] while approximately 50% of Asians possess the decreased functioning CYP2D6*10 allele.[22]

Ligands

Following is a table of selected substrates, inducers and inhibitors of CYP2D6. Where classes of agents are listed, there may be exceptions within the class.

Inhibitors of CYP2D6 can be classified by their potency, such as:

  • Strong inhibitor being one that causes at least a 5-fold increase in the plasma AUC values of sensitive substrates metabolized through CYP2D6, or more than 80% decrease in clearance thereof.[27]
  • Moderate inhibitor being one that causes at least a 2-fold increase in the plasma AUC values of sensitive substrates metabolized through CYP2D6, or 50-80% decrease in clearance thereof.[27]
  • Weak inhibitor being one that causes at least a 1.25-fold but less than 2-fold increase in the plasma AUC values of sensitive substrates metabolized through CYP2D6, or 20-50% decrease in clearance thereof.[27]
Selected inducers, inhibitors and substrates of CYP2D6
Substrates
↑ = bioactivation by CYP2D6		 Inhibitors Inducers

Strong

Moderate

Weak

Unspecified potency

Strong

Unspecified potency

Dopamine biosynthesis

Шаблон:Catecholamine and trace amine biosynthesis

References

Шаблон:Reflist

Further reading

Шаблон:Refbegin

Шаблон:Refend

External links

Шаблон:PDB Gallery Шаблон:Cytochrome P450 Шаблон:Dioxygenases Шаблон:Enzymes Шаблон:Portal bar

Партнерские ресурсы
Криптовалюты
Магазины
Хостинг
Разное

  1. ↑ 1,0 1,1 Шаблон:Cite journal
  2. ↑ Шаблон:Cite journal
  3. ↑ 3,0 3,1 Шаблон:Cite journal
  4. ↑ Шаблон:Cite journal
  5. ↑ Шаблон:Cite book
  6. ↑ Шаблон:Cite book
  7. ↑ Шаблон:Cite journal
  8. ↑ Шаблон:Cite journal
  9. ↑ Шаблон:Cite journal
  10. ↑ Шаблон:Cite journal
  11. ↑ Шаблон:Cite journal
  12. ↑ Шаблон:Cite journal
  13. ↑ Шаблон:Cite journal
  14. ↑ Шаблон:Cite web
  15. ↑ 15,0 15,1 Шаблон:Cite journal
  16. ↑ Шаблон:Cite journal
  17. ↑ Шаблон:Cite journal
  18. ↑ Шаблон:Cite journal
  19. ↑ Шаблон:Cite web
  20. ↑ Шаблон:Cite web
  21. ↑ 21,0 21,1 Шаблон:Cite web
  22. ↑ 22,0 22,1 22,2 Шаблон:Cite journal
  23. ↑ Шаблон:Cite book
  24. ↑ Шаблон:Cite journal
  25. ↑ Шаблон:Cite journal
  26. ↑ Шаблон:Cite journal
  27. ↑ 27,00 27,01 27,02 27,03 27,04 27,05 27,06 27,07 27,08 27,09 27,10 27,11 27,12 27,13 27,14 27,15 27,16 27,17 27,18 27,19 27,20 27,21 27,22 27,23 27,24 27,25 27,26 27,27 27,28 27,29 27,30 27,31 27,32 27,33 27,34 27,35 27,36 27,37 27,38 27,39 27,40 27,41 27,42 27,43 27,44 27,45 27,46 27,47 27,48 27,49 27,50 27,51 27,52 27,53 27,54 27,55 27,56 27,57 27,58 27,59 27,60 27,61 27,62 27,63 27,64 27,65 27,66 27,67 27,68 27,69 27,70 27,71 27,72 27,73 27,74 27,75 27,76 27,77 27,78 27,79 27,80 27,81 27,82 27,83 Шаблон:Cite web Retrieved in July 2011
  28. ↑ 28,00 28,01 28,02 28,03 28,04 28,05 28,06 28,07 28,08 28,09 28,10 28,11 28,12 28,13 28,14 28,15 28,16 28,17 28,18 28,19 28,20 28,21 28,22 28,23 28,24 28,25 28,26 28,27 28,28 28,29 28,30 28,31 28,32 FASS (drug formulary): Swedish environmental classification of pharmaceuticals Facts for prescribers (Fakta för förskrivare), retrieved July 2011
  29. ↑ 29,0 29,1 Шаблон:Cite journal
  30. ↑ Шаблон:Cite web
  31. ↑ Шаблон:Cite journal
  32. ↑ Шаблон:Cite web
  33. ↑ 33,0 33,1 Ошибка цитирования Неверный тег <ref>; для сносок CYP2D6 tyramine-dopamine metabolism не указан текст
  34. ↑ Шаблон:Cite journal
  35. ↑ Шаблон:Cite journal
  36. ↑ 36,0 36,1 Шаблон:Cite web
  37. ↑ Шаблон:Cite web
  38. ↑ Шаблон:Cite journal
  39. ↑ Шаблон:Cite journal
  40. ↑ Шаблон:Cite web
  41. ↑ Шаблон:Cite journal
  42. ↑ Шаблон:Cite journal
  43. ↑ Шаблон:Cite journal
  44. ↑ Шаблон:Cite journal
  45. ↑ 45,0 45,1 Шаблон:Cite web
  46. ↑ Шаблон:Cite web
  47. ↑ 47,0 47,1 Шаблон:Cite journal
  48. ↑ Шаблон:Cite journal
  49. ↑ Шаблон:Cite journal
  50. ↑ Шаблон:Cite journal
  51. ↑ Шаблон:Cite journal
  52. ↑ Шаблон:Cite journal
  53. ↑ 53,0 53,1 53,2 53,3 FASS, The Swedish official drug catalog > Kodein Recip Last reviewed 8 April 2008
  54. ↑ Шаблон:Cite journal
  55. ↑ Шаблон:Cite journal
  56. ↑ Шаблон:Cite journal
  57. ↑ Шаблон:Cite journal
  58. ↑ Шаблон:Cite journal
Источник — http://wikihandbk.com/ruwiki/index.php?title=Английская_Википедия:CYP2D6&oldid=13718144